Moving towards individualized medicine with pharmacogenomics (original) (raw)

References

  1. Evans, W. E. & Relling, M. V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487–491 (1999).
    Article CAS Google Scholar
  2. Vesell, E. S. Pharmacogenetic perspectives gained from twin and family studies. Pharmacol. Ther. 41, 535–552 (1989).
    Article CAS Google Scholar
  3. Guengerich, F. P. et al. Twenty years of biochemistry of human P450s: purification, expression, mechanism, and relevance to drugs. Drug Metab. Dispos. 26, 1175–1178 (1998).
    CAS PubMed Google Scholar
  4. Meyer, U. A. & Zanger, U. M. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu. Rev. Pharmacol. Toxicol. 37, 269–296 (1997).
    Article CAS Google Scholar
  5. Gonzalez, F. J. et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331, 442–446 (1988).
    Article ADS CAS Google Scholar
  6. Evans, W. E. & Johnson, J. A. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu. Rev. Genomics Hum. Genet. 2, 9–39 (2001).
    Article CAS Google Scholar
  7. Weinshilboum, R. Inheritance and drug response. N. Engl. J. Med. 348, 529–537 (2003).
    Article Google Scholar
  8. Evans, W. E. & McLeod, H. L. Pharmacogenomics — drug disposition, drug targets, and side effects. N. Engl. J. Med. 348, 538–549 (2003).
    Article CAS Google Scholar
  9. Evans, W. E. et al. Preponderance of thiopurine _S_-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J. Clin. Oncol. 19, 2293–2301 (2001).
    Article CAS Google Scholar
  10. Evans, W. E., Horner, M., Chu, Y. Q., Kalwinsky, D. & Roberts, W. M. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J. Pediatr. 119, 985–989 (1991).
    Article CAS Google Scholar
  11. Marshall, E. Preventing toxicity with a gene test. Science 302, 588–590 (2003).
    Article CAS Google Scholar
  12. Abbott, A. With your genes? Take one of these, three times a day. Nature 425, 760–762 (2003).
    Article ADS CAS Google Scholar
  13. Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K. & Sadee, W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. J. Am. Med. Assoc. 286, 2270–2279 (2001).
    Article CAS Google Scholar
  14. Eichelbaum, M., Spannbrucker, N. & Dengler, H. J. _N_-oxidation of sparteine in man and its interindividual differences. Naunyn Schmiedebergs Arch. Pharmacol. 287, R94 (1975).
    PubMed Google Scholar
  15. Mahgoub, A., Idle, J. R., Dring, L. G., Lancaster, R. & Smith, R. L. Polymorphic hydroxylation of Debrisoquine in man. Lancet 2, 584–586 (1977).
  16. Ingelman-Sundberg, M., Oscarson, M. & McLellan, R. A. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol. Sci. 20, 342–349 (1999).
    Article CAS Google Scholar
  17. Cheok, M. H. et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nature Genet. 34, 85–90 (2003).
    Article CAS Google Scholar
  18. Buetow, K. H. et al. High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc. Natl Acad. Sci. USA 98, 581–584 (2001).
    Article ADS CAS Google Scholar
  19. Liotta, L. A., Kohn, E. C. & Petricoin, E. F. Clinical proteomics: personalized molecular medicine. J. Am. Med. Assoc. 286, 2211–2214 (2001).
    Article CAS Google Scholar
  20. Golub, T. R. Mining the genome for combination therapies. Nature Med. 9, 510–511 (2003).
    Article CAS Google Scholar
  21. Stegmaier, K. et al. Gene expression-based high-throughput screening (GE-HTS) and application to leukemia differentiation. Nature Genet. 36, 257–263 (2004).
    Article CAS Google Scholar
  22. Evans, W. E. & Guy, R. K. Gene expression as a drug discovery tool. Nature Genet. 36, 214–215 (2004).
    Article CAS Google Scholar
  23. Mallal, S. et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359, 727–732 (2002).
  24. Kuehl, P. et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genet. 27, 383–391 (2001).
    Article CAS Google Scholar
  25. Holden, C. Race and medicine. Science 302, 594–596 (2003).
    Article CAS Google Scholar
  26. Rosenberg, N. A. et al. Genetic structure of human populations. Science 298, 2381–2385 (2002).
    Article ADS CAS Google Scholar
  27. Burchard, E. G. et al. The importance of race and ethnic background in biomedical research and clinical practice. N. Engl. J Med. 348, 1170–1175 (2003).
    Article Google Scholar
  28. Eccles, D. M. Genetic testing for BRCA1 mutation in the UK. Lancet 361, 178–179 (2003).
    Article Google Scholar
  29. Altman, R. B. et al. Indexing pharmacogenetic knowledge on the World Wide Web. Pharmacogenetics 13, 3–5 (2003).
    Article Google Scholar
  30. Goldstein, D. B., Tate, S. K. & Sisodiya, S. M. Pharmacogenetics goes genomic. Nature Rev. Genet. 4, 937–947 (2003).
    Article CAS Google Scholar

Download references